Gilead Sciences: Lymphoma, Follicular trials

The registry lists 11 Lymphoma, Follicular studies with Gilead Sciences as lead sponsor. 1 are open to participants now and 5 have results posted.

Phase 1 4Phase 2 5Phase 3 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene CiloleucelAvailableNCT05776160
• A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin LymphomaCompletedNCT03105336Phase 2Results posted
• Dose Optimization Study of Idelalisib in Follicular LymphomaTerminatedNCT02536300Phase 3Results posted
• Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic LymphomaTerminatedNCT02258529Phase 2Results posted
• Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade LymphomaCompletedNCT01306643Phase 1/2Results posted
• Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin LymphomasCompletedNCT01282424Phase 2Results posted
• Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular LymphomaActive, not recruitingNCT05371093Phase 3
• Safety Profile of Idelalisib in Patients With Refractory Follicular LymphomaCompletedNCT03568929
• Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic LymphomaTerminatedNCT02258555Phase 1
• Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLLTerminatedNCT01728207Phase 1
• Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLLCompletedNCT00546793Phase 1/2